Porcine factor VIII: Current status and future developments

Haemophilia

Volumn 8, Issue SUPPL. 1, 2002, Pages 24-27

  Hay, C R M ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Future; Porcine; VIIIC present

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; DETERGENT; PROTEIN; SOLVENT; VON WILLEBRAND FACTOR; ANTIBODY; BLOOD CLOTTING FACTOR 8;

ARTICLE; BLEEDING DISORDER; BLOOD TRANSFUSION REACTION; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PURIFICATION; DRUG SAFETY; DRUG SCREENING; HEMOPHILIA; HUMAN; ION EXCHANGE CHROMATOGRAPHY; PARVOVIRUS; PRIORITY JOURNAL; RECIPIENT; RELATIVE DENSITY; SCREENING; STORAGE TEMPERATURE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VIRUS ATTENUATION; VIRUS INFECTION; ANIMAL; BLEEDING; BLOOD; DRUG CONTAMINATION; IMMUNOLOGY; INFUSION; INSTRUMENT STERILIZATION; REVIEW; SAFETY; SWINE;

ANIMALS; ANTIBODIES; CONSUMER PRODUCT SAFETY; DRUG CONTAMINATION; FACTOR VIII; HEMORRHAGE; HUMANS; INFUSIONS, PARENTERAL; STERILIZATION; SWINE;

EID: 0036207147     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00125.x     Document Type: Article

References (15)

1. Polyelectrolyte and preparation of factor VIIIC
2. Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of haemophiliacs with antibodies to factor VIII
3. The use of porcine factor VIII:C in the treatment of patients with inhibitor antibodies to VIIIC: A multicenter US trial
4. Safety profile of porcine factor VIII and its use as hospital and home therapy for patients with haemophilia-A and inhibitors: The results of an international survey
5. Use of porcine factor VIII in the treatment of patients with acquired haemophilia
6. Interaction of porcine von Willebrand factor with the platelet glycoproteins 1B and IIb/IIIa complex
7. Platelet activation by porcine factor VIII (Hyate: C)
8. Induction of immune-tolerance in patients with haemophilia A and inhibitors treated with porcine FVIII:C by home therapy
9. Continuous infusion of Porcine factor VIII (Hyate: C, Ipsen)
10. Absence of porcine parvovirus transmission to man
11. Porcine factor VIII: Its role in the management of congenital and acquired inhibitors
12. Viral pharmacovigilance study of haemophiliacs receiving porcine factor VIII
13. Human anti-factor VIII antibodies: Epitope localisation and inhibitory function
14. Analysis of factor VIII inhibitors using hybrid human/porcine factor VIII
15. Coagulant properties of hybrid human/porcine factor VIII molecules